SCHEMBL6345609

SCHEMBL6345609

ICc1cn(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 15/20 0.45
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
ENPP2 Q13822 1/20 0.39
NMBR P28336 1/20 0.34
MEN1 O00255 1/20 0.33
SLC22A1 O15245 1/20 0.33
KCNN4 O15554 1/20 0.33
NR1I2 O75469 1/20 0.33
GMNN O75496 1/20 0.33
USP2 O75604 1/20 0.33
TRPM2 O94759 1/20 0.33
ABCB11 O95342 1/20 0.33
EGFR P00533 1/20 0.33
CA2 P00918 1/20 0.33
LMNA P02545 1/20 0.33
NR3C1 P04150 1/20 0.33
ERBB2 P04626 1/20 0.33
TP53 P04637 1/20 0.33
CYP17A1 P05093 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8125239 0.87 SIRT2 (0.49) SIRT2CYP11B1CYP11B2ENPP2NMBR
SCHEMBL759 0.83 SIRT2 (0.45) SIRT2CYP11B1CYP11B2ENPP2NMBR
SCHEMBL2038903 0.83 SIRT2 (0.45) SIRT2CYP11B1CYP11B2ENPP2NMBR
SCHEMBL6355465 0.83 SIRT2 (0.45) SIRT2CYP11B1CYP11B2ENPP2NMBR
SCHEMBL1342 0.83 SIRT2 (0.45) SIRT2CYP11B1CYP11B2ENPP2NMBR
SCHEMBL1924923 0.83 SIRT2 (0.45) SIRT2CYP11B1CYP11B2ENPP2NMBR
SCHEMBL7269738 0.83 SIRT2 (0.50) SIRT2CYP11B1CYP11B2ENPP2NMBR
SCHEMBL8687551 0.81 SIRT2 (0.44) SIRT2CYP11B1CYP11B2ENPP2NMBR
Hydrochloric Acid SCHEMBL6926362 0.81 SIRT2 (0.44) SIRT2CYP11B1CYP11B2ENPP2NMBR
SCHEMBL6771514 0.81 SIRT2 (0.44) SIRT2CYP11B1CYP11B2ENPP2NMBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2000474-A1 METHOD FOR PRODUCTION OF PEPTIDE THIOESTER COMPOUND Otsuka Chemical Co., Ltd. (JP) 2008-12-10 EP disclosed
US-20080221152-A1 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS ALLERGAN, INC. (US) 2008-09-11 US disclosed
US-6951944-B2 Production of imidazole derivatives and novel intermediates of the derivatives AZWELL INC. (JP) 2005-10-04 US disclosed
US-20050043277-A1 Production of imidazole derivatives and novel intermediates of the derivatives AZWELL INC. (JP) 2005-02-24 US disclosed
EP-1477487-A1 IMPROVEMENT IN THE PRODUCTION OF IMIDAZOLE DERIVATIVES AND NOVEL INTERMEDIATES OF THE DERIVATIVES Azwell Inc. (JP) 2004-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221152-A1 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS ADRB2, ADRA2C, ADRA2A SIRT2 1298/4885CYP11B1 181/4885CYP11B2 84/4885
US-20050043277-A1 Production of imidazole derivatives and novel intermediates of the derivatives HRH3, HRH4, HRH2 SIRT2 1941/4885CYP11B1 3388/4885CYP11B2 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.